Long‐lasting cross‐presentation of tumor antigen in human DC

F Faure, A Mantegazza, C Sadaka… - European journal of …, 2009 - Wiley Online Library
F Faure, A Mantegazza, C Sadaka, C Sedlik, F Jotereau, S Amigorena
European journal of immunology, 2009Wiley Online Library
DC cross‐present exogenous antigens on MHC class I molecules, a process required for the
onset of anti‐tumor immune responses. In order to study the cross‐presentation of tumor
antigens by human DC, we compared the pathways of cross‐presentation of long peptides
requiring internalization and intracellular processing with the direct presentation of short
peptides, which does not require intracellular processing. We found that, after brief
incubations with DC, short peptides were presented to CD8+ T cells with higher efficiencies …
Abstract
DC cross‐present exogenous antigens on MHC class I molecules, a process required for the onset of anti‐tumor immune responses. In order to study the cross‐presentation of tumor antigens by human DC, we compared the pathways of cross‐presentation of long peptides requiring internalization and intracellular processing with the direct presentation of short peptides, which does not require intracellular processing. We found that, after brief incubations with DC, short peptides were presented to CD8+ T cells with higher efficiencies than long peptides. After longer times of chase in the absence of peptide, however, the efficiency of presentation of the two types of peptides was reversed. After 2–3 days, DC pulsed with long peptides still activated T cells efficiently, while DC pulsed with short peptides failed to do so. Long‐lasting presentation of the long peptides was, at least in part, due to a stored persistent pool of antigen, which was still available for loading on MHC class I molecules after several days of chase. These results show that the use of long synthetic peptides allows the efficient, long‐lasting, presentation of tumor antigens, suggesting that long peptides represent an interesting approach for active anti‐tumor vaccination.
Wiley Online Library